These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16255676)

  • 1. Benign prostatic hyperplasia: an insight into current investigational medical therapies.
    Tiwari A; Krishna NS; Nanda K; Chugh A
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1359-72. PubMed ID: 16255676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options.
    Sandhu JS; Vaughan ED
    Drugs Aging; 2005; 22(11):901-12. PubMed ID: 16323969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
    Thiyagarajan M
    Pharmacology; 2002 Jul; 65(3):119-28. PubMed ID: 12037374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
    Chapple CR
    BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists.
    Monda JM; Oesterling JE
    Mayo Clin Proc; 1993 Jul; 68(7):670-9. PubMed ID: 7688840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging drug therapies for benign prostatic hyperplasia.
    Bullock TL; Andriole GL
    Expert Opin Emerg Drugs; 2006 Mar; 11(1):111-23. PubMed ID: 16503830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia.
    Tiwari A
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1425-39. PubMed ID: 17714028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign prostatic hyperplasia. Practical treatment guidelines.
    Tammela T
    Drugs Aging; 1997 May; 10(5):349-66. PubMed ID: 9143856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.
    Kumar R; Malla P; Kumar M
    Expert Opin Drug Discov; 2013 Aug; 8(8):1013-27. PubMed ID: 23662859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for the prostate.
    Harv Mens Health Watch; 2005 Jun; 9(11):3-8. PubMed ID: 16138402
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drugs for the treatment of benign prostatic hypertrophy].
    Caprino L
    Minerva Urol Nefrol; 2000 Jun; 52(2):87-92. PubMed ID: 11085067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current role for combination therapy in male LUTS.
    Chung DE; Kaplan SA
    Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    Kulig K; Malawska B
    Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine therapies for symptomatic benign prostatic hyperplasia.
    Oesterling JE
    Urology; 1994 Feb; 43(2 Suppl):7-16. PubMed ID: 7509536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Combination therapy in benign prostatic hyperplasia (BPH)].
    Desgrandchamps F
    Ann Urol (Paris); 2004 Dec; 38 Suppl 2():S24-8. PubMed ID: 15651487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evidence-based approach to understanding the pharmacological class effect in the management of prostatic diseases.
    Evans CP; Fleshner N; Fitzpatrick JM; Zlotta AR
    BJU Int; 2005 Apr; 95(6):743-9. PubMed ID: 15794775
    [No Abstract]   [Full Text] [Related]  

  • 19. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia.
    Shore N
    Expert Opin Investig Drugs; 2010 Feb; 19(2):305-10. PubMed ID: 20050813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
    Cooper KL; McKiernan JM; Kaplan SA
    Drugs; 1999 Jan; 57(1):9-17. PubMed ID: 9951948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.